Ozempic lowers Alzheimer’s risk: Research
The diabetes and weight loss drug Ozempic could lower the risk of Alzheimer's disease among people with Type 2 diabetes, according to a new study published Thursday.
Alzheimer’s disease is the seventh-leading cause of death in the United States, with roughly 120,000 people dying from the disease each year, according to data from the Centers for Disease Control and Prevention.
There are about 7 million people in the U.S. who live with Alzheimer’s, and that number is expected to nearly double by 2050, according to the Alzheimer’s Association.
Researchers at Case Western Reserve University School of Medicine looked at three years' worth of electronic records of almost 1 million people with Type 2 diabetes.
The research group found that people who were prescribed semaglutide — the main ingredient in Ozempic — had a 40 percent to 70 percent reduced risk of developing Alzheimer’s compared to Type 2 diabetics who took one of another seven types of antidiabetic medications, including insulin.
Researchers also compared semaglutide with the use of other GLP-1s like lixisenatide, dulaglutide and liraglutide.
Semaglutide’s possible risk reduction for Alzheimer’s was seen across gender identities, age and weight groups, the study notes.
The study’s findings add to the research showing that GLP-1s, a group of diabetes and weight loss medications, may have more health benefits than boosting weight loss or regulating blood sugar levels.
One study published earlier this month suggests that the main ingredients in Ozempic and Mounjaro may help some people overcome drug and alcohol addictions. Another study published in May suggests that semaglutide may help protect Type 2 diabetics from kidney failure and chronic kidney disease.
It also supports research presented earlier this year suggesting a connection between GLP-1s and reduced Alzheimer’s risk among Type 2 diabetics.
But the Thursday study has limitations because it relies on data gathered from digital health records and requires further investigation, researchers said.
“Our results indicate that further research into semaglutide’s use will need to be further investigated through randomized clinical trials so alternative drugs can be tested as a potential treatment for this debilitating illness,” said Rong Xu, a biomedical informatics professor at Case Western and lead author of the study.
Date: |
Topics
-
Top stories - NBC News
Ozempic linked to lower Alzheimer's risk in people with Type 2 diabetes
10 hours ago -
Business - CNBC
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
10 hours ago -
World - The Guardian
US congress research warns of risk of cost blowouts for Australia in Aukus submarine program
6 days ago - Australia -
Politics - The Hill
Drugmaker wants an end to Ozempic copies
22 hours ago -
Top stories - BBC News
NHS will not fund new drug to slow Alzheimer’s
Yesterday -
Science - The New York Times
What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trials
Yesterday -
Business - Financial Times
ECB lowers rates to 3.25% as inflation slows
October 17 -
Health - ABC News
UK regulator approves second Alzheimer's drug in months but government won't pay for it
Yesterday - United Kingdom
More from The Hill
-
Politics - The Hill
Georgian government officials raid American think tank staff members' homes
29 minutes ago -
Politics - The Hill
Putin name-checks Trump at BRICS summit
33 minutes ago - Donald Trump -
Politics - The Hill
North Koreans training in Russia are now in combat zone: Ukraine Defense Intelligence
37 minutes ago - Ukraine -
Politics - The Hill
Democrats give Harris rocky reviews on CNN town hall
42 minutes ago - Kamala Harris -
Politics - The Hill
House Republican presses Meta on censoring political content
56 minutes ago
Latest in Politics
-
Politics - The Hill
Georgian government officials raid American think tank staff members' homes
29 minutes ago -
Politics - The Hill
Putin name-checks Trump at BRICS summit
33 minutes ago - Donald Trump -
Politics - The Hill
North Koreans training in Russia are now in combat zone: Ukraine Defense Intelligence
37 minutes ago - Ukraine -
Politics - The Hill
Democrats give Harris rocky reviews on CNN town hall
42 minutes ago - Kamala Harris -
Politics - NBC News
Former Republican Congressman backing Harris: ‘We have to work together’
44 minutes ago